1 active not recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Mezigdomide: new trials by email Literature Review of Mezigdomide trials Research Report on Mezigdomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Mezigdomide, Carfilzomib, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 606 | 2023-01-10 | 2026-09-24 |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) mezigdomide, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | Celgene | 810 | 2022-09-20 | 2026-10-30 |
Multiple Myeloma (2) · Recurrence (2)
Bristol-Myers Squibb (1) · Celgene (1)
Argentina (2) · Australia (2) · Austria (2) · Brazil (2) · Canada (2) · China (2) · Germany (2) · Greece (2) · India (2) · Israel (2) · Italy (2) · Japan (2) · Puerto Rico (2) · Romania (2) · South Korea (2)
2023 (1)